KE — Kimball Electronics, Inc. · 2026-09-06 · Verdict: WATCH · Conviction 3

Price $25.03 (screen close, 2026-09-05) · Mkt cap $599.9M · EV $627.2M (screen basis, pre-Helvoet); ~$730M pro forma for the July 1 acquisition · EV/EBIT 10.4x pro forma on FY2027 guided adjusted operating income · FCF yield 3.4% on real FY2026 free cash flow (screen's 25.1% is stale) · Net debt $27.3M reported, ~$130M pro forma · ADV20 $5.5M Sources read: 10-K filed 2026-08-19 for FY ended 2026-06-30 (Items 1, 1A, 7), 10-Q filed 2026-05-06 (Q3 MD&A), DEF 14A filed 2025-09-25, 8-Ks 2026-03-19, 2026-05-05, 2026-07-01 and 2026-08-12 with EX-99 exhibits, Form 4 summary (12m), triage note 2026-09-04. No transcript in the pack.

1. What the business actually does

Kimball is a mid-sized contract manufacturer of durable, high-reliability electronics, building circuit board assemblies and finished products to customers' designs in eleven plants across eight countries. FY2026 sales of $1,431.4M split automotive 46%, medical 29%, industrial 25%, reported as a single segment. Alongside it the company is assembling a second business: contract development and manufacturing of medical disposables, precision molded plastics and drug delivery devices, branded "Kimball Solutions," with a shareholder vote on 2026-11-13 to rename the company and change the ticker to KMBL (10-K 2026, Item 1).

2. Why it is mispriced — the edge case

The edge is a misunderstood segment, and a real one. The consolidated line looks like a shrinking, 4.6%-margin EMS shop: sales fell 4% in FY2026 and 13% in FY2025. Underneath, medical grew over 10% once FY2025 is normalized for a one-off $24M consigned inventory sale (Q4 release, 2026-08-12), and on 2026-07-01 the company bought Helvoet Polymer Technologies for about $103M, adding roughly $60M of medical CDMO sales at a mid-teens EBITDA margin versus Kimball's 7.3% consolidated (8-K 2026-07-01, EX-99.1). Management guides medical past a third of FY2027 sales.

Who is indifferent: ownership is almost entirely passive. Vanguard 7.6%, Dimensional 7.3%, BlackRock 7.1%, Managed Account Advisors 5.9%, all officers and directors together 2.8% (DEF 14A, 2025-09-15). No strategic holder, no activist, a $5.5M ADV that keeps most institutions out.

But the screen's cheapness is false. Its 25.1% FCF yield comes from FY2025 cash flow of $183.9M, a working capital release: receivables provided $71.8M and inventories $74.6M as sales fell. FY2026 operating cash flow was $72.3M against $51.7M of capex, so real free cash flow was $20.6M, a 3.4% yield (10-K 2026, Item 7).

3. Unit economics and growth

Gross margin improved to 8.2% from 7.0% on European volume leverage, the Tampa closure and currency. Adjusted operating income was $65.7M, 4.6% of sales, up from 4.1%; that figure adds back $8.2M of stock compensation, so the honest number is nearer $57.5M, a 4.0% margin. Adjusted EBITDA was $104.4M on $38.7M of D&A (Q4 release reconciliation).

Customer concentration is heavy: Nexteer 18%, Philips 11%, ZF 11%, together 40% of sales, and total customers fell from 65 to 58 to 50 over three years, though the departures were about 1% of sales. Automotive fell 7% to $656.9M on a lost major program unrelated to Kimball plus tariff-driven demand pressure; open orders were flat at $643M. Pricing power is weak by the company's own admission: MD&A says efficiencies and material pricing drive prices down over a project's life, and expects that to continue.

The tax line is the most under-discussed number here. The FY2026 effective rate was 47.5%, on dividend withholding taxes from foreign subsidiaries and GILTI, against US pre-tax income of just $2.6M versus $50.7M foreign, and $85M of the $88.9M cash sits offshore (all 10-K 2026, Item 7). Operating multiples flatter this company; after-tax earnings do not.

4. Balance sheet and capital allocation

Debt at year end was $116.6M, the lowest in over four years, against $88.9M of cash and $322.4M of borrowing capacity (Q4 release). The restated $300M revolver runs to 2031 and the term loan to 2029, covenants complied with (10-K 2026, Item 7). Helvoet was funded from cash and the revolver, so pro forma net debt is roughly $130M, under 1.3x adjusted EBITDA. Buybacks are modest: $11.9M for 447,000 shares in FY2026 and $115.6M of the $140M authorization used, leaving about $24M; basic share count fell 1.1%. Form 4s over twelve months show zero open-market purchases and zero sales across 49 rows. Comp is tied to operating income margin, economic profit and relative TSR (DEF 14A).

5. Management: said versus did

In May 2026 management affirmed FY2026 sales of $1,400-1,460M, adjusted operating margin of 4.2-4.5% at the high end, and capex of $50-60M (8-K 2026-05-05). It delivered $1,431.4M, a 4.6% margin above the guided high end, and $51.7M of capex. A clean hit. The FY2027 guide cuts the other way: sales of $1,535-1,560M but adjusted operating margin of only 4.4-4.7%, flat, despite consolidating a mid-teens-margin business. The accretion is absorbed by Helvoet purchase accounting and by start-up costs and depreciation at the new Indianapolis CDMO facility, both named as FY2027 headwinds (10-K 2026, Item 7).

6. Valuation

Pro forma EV is about $730M. FY2027 guided adjusted operating income at the midpoint is $70.4M, so 10.4x, or roughly 6.2x estimated adjusted EBITDA.

Bear (30%): automotive erosion outruns medical, Indianapolis and integration costs hold margin at 4.4%, sales flat at $1,535M, EBITDA $115M at a 5.5x trough EMS multiple. Equity $503M, $21 a share; book value of $24.41 is a soft floor only. Base (45%): FY2027 lands on guidance, FY2028 grows 4% organically with Indianapolis ramped, sales $1,620M at a 5.2% margin, EBITDA $134M at 6.5x. Equity $771M, $32 a share in two years. Bull (25%): medical passes 40% of sales by FY2029, margin reaches 6.5% on $1.75B, EBITDA $165M at 8x for a medical CDMO mix. Equity $1.27B, $53 a share. Probability weighted: about $34 versus $25.03, roughly 36% upside over two to three years.

Reverse DCF: at $730M of enterprise value, a 10% cost of capital and 2.5% terminal growth, the price implies steady-state NOPAT of about $55M against roughly $34M today once stock compensation is expensed at the 45%-plus tax rate, so it requires real operating margin to go from about 4.0% to 6.5% on flat sales, or the equivalent from growth.

7. Catalysts

Q1 FY2027 results in early November, the first quarter consolidating Helvoet and the first read on medical flow-through. The KMBL ticker change at the 2026-11-13 meeting, cosmetic but forcing quant and index reclassification. Indianapolis becoming fully operational and the start-up drag ending. Board refresh of the nearly exhausted repurchase authorization.

8. Risks and pre-registered kill criteria

Risks (10-K 2026, Item 1A): 46% automotive exposure with Nexteer and ZF under cyclical and in-sourcing pressure; Helvoet is the largest acquisition in company history, integrating across India and the EU; FDA, MDR and IVDR regimes now cover more of the business. Kill criteria: 1. Adjusted operating margin below 4.4%, the low end of guidance, in two consecutive FY2027 quarters. 2. Medical below one third of net sales in every FY2027 quarter, despite Helvoet being in the numbers. 3. Automotive sales below $600M in FY2027, against $656.9M in FY2026. 4. Net debt above $200M at any quarter end with buybacks suspended.

9. Verdict and summary

WATCH, conviction 3. Kimball has a real mix shift but is fairly priced, not cheap, and the screen that surfaced it was wrong about why: its 25% FCF yield is a stale FY2025 working capital release, real FY2026 free cash flow was $20.6M or 3.4%, and a 47.5% tax rate on offshore earnings leaves roughly $34M of NOPAT against a $730M pro forma enterprise value. What is genuinely interesting is that medical grew over 10% normalized while the consolidated line fell 4%, and that management spent $103M on Helvoet at about 9x EBITDA for a mid-teens-margin medical CDMO, guiding medical past a third of FY2027 sales. It earned credibility by beating its own FY2026 margin guide. But the FY2027 guide holds adjusted margin flat at 4.4-4.7% despite adding that higher-margin business, because Indianapolis start-up costs and purchase accounting absorb all of it. At $25.03 you pay 10.4x guided operating income and 1.03x book to wait a year for proof. Until margin breaks above 5%, a skeptic can fairly call it an average EMS company with a good story.

Research for discussion, not investment advice. Positions and sizing are the reader's decision.